Quantbot Technologies LP Trims Position in Certara, Inc. (NASDAQ:CERT)

Quantbot Technologies LP trimmed its position in Certara, Inc. (NASDAQ:CERT) by 37.3% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 58,227 shares of the company’s stock after selling 34,661 shares during the period. Quantbot Technologies LP’s holdings in Certara were worth $620,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the company. Charles Schwab Investment Management Inc. grew its position in Certara by 1.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 699,575 shares of the company’s stock valued at $8,192,000 after buying an additional 12,720 shares during the period. Glenmede Trust Co. NA grew its position in shares of Certara by 78.6% during the 3rd quarter. Glenmede Trust Co. NA now owns 1,206,069 shares of the company’s stock valued at $14,123,000 after acquiring an additional 530,598 shares during the period. Edgestream Partners L.P. bought a new position in Certara in the 3rd quarter worth $1,782,000. Wasatch Advisors LP raised its holdings in Certara by 22.4% in the 3rd quarter. Wasatch Advisors LP now owns 9,015,941 shares of the company’s stock worth $105,577,000 after purchasing an additional 1,651,076 shares during the period. Finally, 272 Capital LP purchased a new position in Certara during the third quarter valued at $177,000. 73.96% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of analysts have commented on the company. Barclays upped their price target on Certara from $12.00 to $13.00 and gave the stock an “equal weight” rating in a research report on Friday, February 28th. Stephens restated an “overweight” rating and set a $17.00 target price on shares of Certara in a research note on Thursday, February 27th. William Blair reaffirmed a “market perform” rating on shares of Certara in a report on Thursday, February 27th. Finally, TD Cowen initiated coverage on shares of Certara in a research note on Thursday, February 27th. They issued a “buy” rating and a $16.00 price objective for the company. Four analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Certara currently has a consensus rating of “Moderate Buy” and an average target price of $15.83.

Certara Trading Down 0.3 %

Shares of CERT opened at $10.12 on Friday. The firm has a market cap of $1.63 billion, a P/E ratio of -50.60, a price-to-earnings-growth ratio of 9.29 and a beta of 1.60. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.86 and a quick ratio of 2.86. Certara, Inc. has a 1 year low of $9.41 and a 1 year high of $19.18. The company has a 50 day simple moving average of $12.47 and a two-hundred day simple moving average of $11.46.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.